Oral tablet Sunitinib lowers risk of kidney cancer return: Study
Tuesday, October 11, 2016 - 13:32
in Health & Medicine
Ryan MaassGUILDFORD, England, Oct. 11 (UPI) -- Doctors say a successful clinical trial of the oral tablet Sunitinib in kidney cancer patients shows it reduces the likelihood of cancer returning.